MEK INHIBITOR TRAMETINIB IN HIGH GRADE OVARIAN CANCER PROLIFERATION

被引：0
|
作者：
Chesnokov, Mikhail [1 ]
Jamroze, Anmbreen [1 ]
Ha, Wootae [1 ]
Chefetz, Ilana [1 ]
机构：
[1] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA
来源：
CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GMM-019
引用
收藏
页码：82 / 82
页数：1
相关论文
共 50 条
  • [1] Adaptive responses of low-grade ovarian cancer cell lines to MEK inhibitor
    Wong, Kwong-Kwok
    Tsang, Yvonne T.
    Chen, Michelle
    Kun, Eucharist H.
    Gershenson, David M.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [2] Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer
    Mert, Ismail
    Chhina, Jasdeep
    Allo, Ghassan
    Dai, Jing
    Seward, Shelly
    Carey, Mark S.
    Llaurado, Marta
    Giri, Shailendra
    Rattan, Ramandeep
    Munkarah, Adnan R.
    GYNECOLOGIC ONCOLOGY, 2017, 146 (02) : 319 - 326
  • [3] The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells
    Kim, Seo Yun
    Jeong, Eun-Hui
    Lee, Tae-Gul
    Kim, Hye-Ryoun
    Kim, Cheol Hyeon
    ANTICANCER RESEARCH, 2021, 41 (06) : 2885 - 2894
  • [4] Trametinib: a MEK inhibitor for management of metastatic melanoma
    Lugowska, Iwona
    Kosela-Paterczyk, Hanna
    Kozak, Katarzyna
    Rutkowski, Piotr
    ONCOTARGETS AND THERAPY, 2015, 8 : 2251 - 2259
  • [5] The MEK inhibitor trametinib for the treatment of advanced melanoma
    Johnson, Douglas B.
    Hames, Megan L.
    Sosman, Jeffrey A.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (12): : 1341 - 1349
  • [6] MEK activation is associated with a molecular subgroup in high grade serous ovarian cancer
    McCabe, Nuala
    Gourley, Charlie
    McGavigan, Andrena
    Michie, Caroline .
    McGivern, Niamh
    Churchman, Michael
    O'Brien, Eamonn J.
    Hill, Laura
    Davison, Timothy S.
    Williams, Alistair
    McCluggage, Glenn
    Keating, Karen E.
    Harkin, Denis P.
    Kennedy, Richard D.
    CANCER RESEARCH, 2016, 76
  • [7] PREDICTORS OF MEK INHIBITOR RESPONSE IN LOW GRADE SEROUS OVARIAN CANCER CELL LINES.
    Carey, M.
    Dawson, A.
    Hoenisch, J.
    Kim, H.
    Chui, K.
    Bamford, S.
    Salamanca, C.
    Cremona, M.
    Anderson, S.
    Volik, S.
    Le Bihan, S.
    Collins, C.
    Morin, G.
    Huntsman, D.
    DiMattia, G.
    Hennessy, B.
    Llaurado-Fernandez, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 135 - 135
  • [8] Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma
    King, Judy W.
    Nathan, Paul D.
    FUTURE ONCOLOGY, 2014, 10 (09) : 1559 - 1570
  • [9] Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS-mutated colorectal cancer
    Ghosh, Susmita
    Fan, Fan
    Powell, Reid
    Park, Yong Sung
    Stephan, Clifford
    Kopetz, E. Scott
    Ellis, Lee M.
    Bhattacharya, Rajat
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [10] ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells
    Zhou, Sheng
    Xia, Hongwei
    Xu, Huanji
    Tang, Qiulin
    Nie, Yongzhan
    Gong, Qi Yong
    Bi, Feng
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
12345